Swedish Orphan Biovitrum Assumes Direct Responsibility For Orfadin® (Nitisinone) In U.S. And Canada And Introduces Orfadin4U™
4/1/2014 10:48:14 AM
STOCKHOLM, Sweden, April 1, 2014 (GLOBE NEWSWIRE) -- Swedish Orphan Biovitrum AB (publ) (Sobi) today assumed direct responsibility for the distribution of its proprietary product Orfadin in the United States and Canada. Orfadin is the only FDA approved therapy for use as an adjunct to dietary restriction of tyrosine and phenylalanine for the treatment of hereditary tyrosinaemia type 1 (HT-1). Sobi has been responsible for the worldwide development and commercialisation of Orfadin since 1993 and currently distributes the product in over 50 countries around the globe.
Help employers find you! Check out all the jobs and post your resume.
comments powered by